LeMaitre Vascular (NASDAQ:LMAT) Price Target Raised to $104.00

LeMaitre Vascular (NASDAQ:LMAT) had its target price increased by Wells Fargo & Company from $94.00 to $104.00 in a research note issued to investors on Wednesday morning,Benzinga reports. They currently have an equal weight rating on the medical instruments supplier’s stock.

LMAT has been the subject of a number of other reports. Barrington Research boosted their target price on shares of LeMaitre Vascular from $95.00 to $105.00 and gave the company an “outperform” rating in a research note on Thursday, February 26th. Citizens Jmp lifted their price objective on LeMaitre Vascular from $113.00 to $118.00 and gave the company a “market outperform” rating in a report on Thursday, February 26th. Roth Mkm restated a “buy” rating and issued a $117.00 price objective (up from $108.00) on shares of LeMaitre Vascular in a report on Thursday, February 26th. Zacks Research upgraded LeMaitre Vascular from a “hold” rating to a “strong-buy” rating in a report on Monday, April 13th. Finally, Freedom Capital upgraded LeMaitre Vascular to a “hold” rating in a report on Tuesday, March 31st. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $112.60.

LeMaitre Vascular Stock Up 0.0%

Shares of LMAT opened at $107.94 on Wednesday. The firm has a market capitalization of $2.47 billion, a P/E ratio of 39.83, a P/E/G ratio of 3.00 and a beta of 0.60. LeMaitre Vascular has a 12-month low of $78.35 and a 12-month high of $118.01. The company has a current ratio of 14.32, a quick ratio of 10.95 and a debt-to-equity ratio of 0.42. The firm has a fifty day moving average price of $110.00 and a 200-day moving average price of $94.48.

LeMaitre Vascular (NASDAQ:LMAT) last issued its earnings results on Tuesday, May 5th. The medical instruments supplier reported $0.68 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.66 by $0.02. The firm had revenue of $66.55 million during the quarter, compared to analyst estimates of $66.67 million. LeMaitre Vascular had a net margin of 24.35% and a return on equity of 15.36%. The business’s revenue was up 11.1% on a year-over-year basis. During the same period in the previous year, the firm earned $0.48 earnings per share. LeMaitre Vascular has set its FY 2026 guidance at 2.930-3.080 EPS and its Q2 2026 guidance at 0.790-0.840 EPS. Equities research analysts expect that LeMaitre Vascular will post 3 earnings per share for the current year.

LeMaitre Vascular Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, June 4th. Investors of record on Thursday, May 21st will be issued a $0.25 dividend. This represents a $1.00 annualized dividend and a dividend yield of 0.9%. The ex-dividend date is Thursday, May 21st. LeMaitre Vascular’s payout ratio is presently 36.90%.

Insider Activity at LeMaitre Vascular

In related news, Director David B. Roberts sold 8,464 shares of LeMaitre Vascular stock in a transaction dated Friday, February 27th. The stock was sold at an average price of $106.80, for a total value of $903,955.20. Following the completion of the sale, the director directly owned 17,979 shares in the company, valued at $1,920,157.20. The trade was a 32.01% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Trent G. Kamke sold 1,044 shares of LeMaitre Vascular stock in a transaction dated Friday, February 27th. The shares were sold at an average price of $110.29, for a total value of $115,142.76. Following the completion of the transaction, the insider owned 6,677 shares in the company, valued at $736,406.33. This trade represents a 13.52% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 215,438 shares of company stock worth $23,062,911 over the last three months. 7.40% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On LeMaitre Vascular

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Illinois Municipal Retirement Fund grew its stake in LeMaitre Vascular by 1.1% in the fourth quarter. Illinois Municipal Retirement Fund now owns 11,171 shares of the medical instruments supplier’s stock valued at $906,000 after purchasing an additional 123 shares during the last quarter. NewEdge Advisors LLC grew its stake in LeMaitre Vascular by 4.6% in the fourth quarter. NewEdge Advisors LLC now owns 3,158 shares of the medical instruments supplier’s stock valued at $256,000 after purchasing an additional 139 shares during the last quarter. State of Alaska Department of Revenue grew its stake in LeMaitre Vascular by 1.2% in the fourth quarter. State of Alaska Department of Revenue now owns 11,986 shares of the medical instruments supplier’s stock valued at $971,000 after purchasing an additional 147 shares during the last quarter. Johnson Investment Counsel Inc. grew its stake in LeMaitre Vascular by 0.5% in the third quarter. Johnson Investment Counsel Inc. now owns 29,792 shares of the medical instruments supplier’s stock valued at $2,607,000 after purchasing an additional 153 shares during the last quarter. Finally, Federated Hermes Inc. grew its stake in LeMaitre Vascular by 0.4% in the second quarter. Federated Hermes Inc. now owns 39,659 shares of the medical instruments supplier’s stock valued at $3,294,000 after purchasing an additional 155 shares during the last quarter. Hedge funds and other institutional investors own 84.64% of the company’s stock.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.